Disease · MONDO_0001051

acute otitis externa

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. acute otitis externa. Diseases, record MONDO_0001051. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0001051

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: acute otitis externa; Open Targets
Open Targets ID: MONDO_0001051; Open Targets
Other names: acute swimmers' ear, otitis externa, acute; Open Targets
Disease Ontology: DOID:10518; Disease Ontology
Highest stage of its drugs: Phase 3, for 6 of its 6 drugs, from ClinicalTrials.gov; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
CIPROFLOXACIN	CHEMBL8	Small molecule	Phase 3	ClinicalTrials.gov	8	8	8	Drugs and targets
DEXAMETHASONE	CHEMBL384467	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
FINAFLOXACIN	CHEMBL1908370	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
FLUOCINOLONE ACETONIDE	CHEMBL989	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DEXAMETHASONE PHOSPHORIC ACID	CHEMBL1201302	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
MOXIFLOXACIN	CHEMBL32	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets1

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes
NR3C1	Glucocorticoid receptor	3	Glucocorticoid receptor agonist	Phase 3	https://conductscience.org/library/genes/2908

Source Drugs and targets

Trials11

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01535599	Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa	Phase 3	768	2014-06-18	Acute Otitis Externa	FINAFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT01535560	Safety and Efficacy Evaluation of Topical AL-60371 Otic Suspension, 0.3% in the Treatment of Acute Otitis Externa	Phase 3	589	2013-12-10	Acute Otitis Externa	FINAFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT02216071	Comparative Efficacy and Safety of Ciprofloxacin 0.3% and Dexamethasone 0.1% in Acute Otitis Externa	Phase 3	499	2021-05-28	Acute Otitis Externa	CIPROFLOXACIN, DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov
NCT03196973	Efficacy and Safety of DF289 Plus DF277 Otic Solution in the Treatment of Acute Otitis Externa	Phase 3	493	2021-04-09	Acute Otitis Externa	CIPROFLOXACIN, FLUOCINOLONE ACETONIDE	Its record names the disease	ClinicalTrials.gov
NCT02801370	Phase 3 Study of OTO-201 in Acute Otitis Externa	Phase 3	262	2020-09-22	Acute Otitis Externa, Swimmer's Ear	CIPROFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT00750633	A Phase III Study of an Otic Formulation in Acute Otitis Externa	Phase 3	990		Acute Otitis Externa	DEXAMETHASONE PHOSPHORIC ACID, MOXIFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT04636957	Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Otic Solution in the Treatment of Acute Otitis Externa	Phase 3	600		Acute Otitis Externa	CIPROFLOXACIN, FLUOCINOLONE ACETONIDE	Its record names the disease	ClinicalTrials.gov
NCT00872209	Safety and Efficacy Study of Foam Otic Cipro Compared to a Standard Solution ( Ciloxan - Alcon Labs ) to Treat Acute Otitis Externa	Phase 1/2	100		Otitis Externa, Otorhinolaryngologic Diseases, Ear Diseases, Otitis	CIPROFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT01359098	Efficacy and Safety of Once-Daily Ciprodexa Otic Foam Compared to Twice-daily Ciprodex Ear Drops in Acute Otitis Externa	Phase 2	100		Otitis Externa, Otorhinolaryngologic Diseases, Ear Diseases, Otitis	CIPROFLOXACIN, DEXAMETHASONE	Its record names the disease	ClinicalTrials.gov
NCT01157819	Safety and Efficacy of Once-Daily Dosing of FoamOtic Cipro Compared to Twice-Daily Dosing of Ciloxan Ear Drops in Patients With Acute External Otitis	Phase 2	70		Otitis Externa, Otorhinolaryngologic Diseases, Ear Diseases, Otitis	CIPROFLOXACIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 11

See all 11 trials

Comparisons in its trials10

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
AL-60371 vs Vehicle: serious adverse events	0 of 344	1 of 342	686	NCT01535599	Trial comparisons
AL-60371 vs Vehicle: serious adverse events	0 of 274	0 of 274	548	NCT01535560	Trial comparisons
Ciprodex®, RLD vs EXL CDOS: Number of Participants With Adverse Events	60 of 247	67 of 252	499	NCT02216071	Trial comparisons
Ciprodex®, RLD vs EXL CDOS: Number of Participants With Clinical Cure of AOE	190 of 254	191 of 245	499	NCT02216071	Trial comparisons
Ciprodex®, RLD vs EXL CDOS: serious adverse events	0 of 247	1 of 252	499	NCT02216071	Trial comparisons
Ciprodex®, RLD vs EXL CDOS: Number of Participants With Microbiological Cure (MC)	115 of 160	117 of 149	309	NCT02216071	Trial comparisons
12 mg OTO-201 vs Control: Number of Subjects Considered a Clinical Cure at Day 15	97 of 130	69 of 130	260	NCT02801370	Trial comparisons
12 mg OTO-201 vs Control: Number of Subjects Considered a Clinical Cure at Day 8	91 of 130	63 of 130	260	NCT02801370	Trial comparisons
12 mg OTO-201 vs Control: deaths from any cause	0 of 127	0 of 132	259	NCT02801370	Trial comparisons
12 mg OTO-201 vs Control: serious adverse events	0 of 127	0 of 132	259	NCT02801370	Trial comparisons

Papers from its trials3

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42892712	DERIVED	2	PubMed
42210509	DERIVED	2	PubMed
35834251	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0001051

GET https://conductscience.org/api/diseases/v1/MONDO_0001051/drugs

API reference For AI assistants